SRSF12 is a prognostic biomarker involved in immune infiltration in acute myeloid leukemia

Acute myeloid leukemia (AML) is a disease characterized by the proliferation of abnormal cells originating from blood stem cells. Understanding the pathogenesis and progression of AML, as well as identifying molecular markers for early diagnosis and prognosis assessment, is of paramount importance. The AML dataset was obtained from the Cancer Genome Atlas (TCGA), while the normal sample dataset was derived from the Genotype-Tissue Expression(GTEx) dataset. Furthermore, the association between SRSF12 expression and drug response was assessed using the Cancer Therapeutic Response Portal (CTRP) database to evaluate its potential therapeutic value. Finally, SRSF12 expression in AML cells was measured using quantitative real-time PCR (qRT-PCR). The difference in SRSF12 expression between 13 types of tumors and normal tissue samples was found to be statistically significant (<i>P</i> &lt; 0.05). SRSF12 exhibited predominantly high expression in AML, indicating its potential as a diagnostic and prognostic marker for AML patients. High expression of SRSF12, along with age and cytogenetic risk, emerged as independent predictors of favorable prognosis in AML patients (<i>P</i> &lt; 0.05). PCR demonstrated a significant increase in SRSF12 expression in AML patients. Overall, our findings suggest that the high expression of SRSF12 in AML patients is a poor prognostic factor, which may provide a new option for the diagnosis, and targeted therapy of AML. <b>What is the context?</b> Acute myeloid leukemia (AML) is a malignant clonal disease originating from hematopoietic stem progenitor cells. It is of great significance to identify the pathogenesis and development of AML and to search for molecular markers for early diagnosis and prognosis assessment. <b>What is new?</b> In this study, the expression of SRSF12 in AML patients was analyzed by bioinformatics and RT-qPCR, and the relationship between clinical traits and prognosis was analyzed, and it was found that SRSF12 was highly expressed in AML tissues, and in addition, high expression of SRSF12 was associated with good prognosis of patients, and its expression was correlated with white blood cell count, FAB stage and cytogenetics. Enrichment analysis showed that SRSF12 was mainly involved in PI3K-AKT signaling pathway, Jak-STA signaling pathway, etc., and the expression of SRSF12 was positively correlated with helper T cell infiltration, but negatively correlated with neutrophil and macrophage infiltration. PPI analysis showed that SRSF12 interacted with SRSF11 and other proteins, and we also found that SRSF12 expression was significantly associated with a variety of drugs in hematopoietic and lymphoid tissues. <b>What is the impact?</b> This study provides further evidence to prove it, SRSF12 may be used as a new potential biomarker to predict the prognosis and guide the precise diagnosis and treatment of patients in the future.